BioSpace News Archive

The FDA is expected to make decisions on Emergent BioSolutions’ sNDA for OTC Narcan and Roche’s Polivy in frontline DLBCL.

Relmada Therapeutics announced it would make key changes to its clinical evaluation of REL-1017 as a possible add-on treatment for major depressive disorder.

Analysts point to a missed secondary endpoint and cardiovascular risks that may delay FDA approval as possible reasons for the unexpected drop in Karuna’s stock following the data reveal.

In a double data drop Thursday, AbbVie touted two clinical trial wins, for Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus.

Upstaza is the first targeted therapy for aromatic L-amino acid decarboxylase (AADC) deficiency. PTC expects to submit a Biologics License Application to the FDA in the first half of 2023.

89bio, Inc. today announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25.

Savaria Corporation (“Savaria”) (TSX: SIS) a global leader in the accessibility industry, declared today a dividend of 4.33 cents ($0.0433) per common share, in accordance with its monthly dividend policy, payable on April 10, 2023, to shareholders of record of the Corporation at the close of business on March 31, 2023.

Ventyx Biosciences, Inc. today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.

Marvin (the “Company”) announced today that it has recently presented a data report regarding mental health and healthcare providers at the 2023 Association for Advancing Physician and Provider Recruitment (AAPPR) annual conference.

Orion Health, a global leader in population health software, is strengthening its position in North America with new technology and the appointment of James Rice as Executive Vice President for North America.